New vaccine aims to stop deadly salmonella strains

NCT ID NCT05480800

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new vaccine designed to protect against two types of Salmonella bacteria that cause serious infections like typhoid fever and invasive nontyphoidal Salmonella disease. The trial involved 155 healthy adults in Europe and Africa who received three doses of the vaccine or a placebo. Researchers checked for side effects and measured the immune response to see if the vaccine is safe and prompts the body to fight the bacteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) and invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA)

What this could lead to

If successful, this vaccine could help prevent serious Salmonella infections that cause fever and bloodstream infections, especially in Africa where they are a major health problem.

What could go wrong

This is an early phase 1/2a trial with only 155 participants, so results may not apply to larger populations. The vaccine may not provide strong enough protection or could have side effects not yet seen.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SALMONELLA INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

salmonellosis invasive non-typhoidal salmonellosis prevention target typhoid fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • GSK Investigational Site

    Edegem, 2650, Belgium

  • GSK Investigational Site

    Blantyre, Malawi